Treatment with Tecentriq plus Zejula and chemotherapy did not offer better outcomes to patients with recurrent ovarian cancer, according to results from a phase 3 trial.
Patients with recurrent ovarian cancer did not experience a statistically significant improvement in clinical outcomes such as progression-free survival and objective response rate with the addition of atezolizumab to chemotherapy and niraparib maintenance therapy.
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
Blocking Immune Molecule Slows Aggressive Childhood Cancer miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Researchers from Cima and the Clínica Universidad de Navarra, together with the international cooperative group Diffuse Midline Glioma (DMG-ACT), have confirmed that blocking an immune checkpoint molecule reduces the tumor and prolongs survival in animal models of the most aggressive childhood cancer. This research, carried out at the Cancer Center Clínica Universidad de Navarra, shows that inhibition of TIM-3 promotes the immune memory of diffuse intrinsic stem glioma (DIPG) and improves the prognosis of the disease.